Impel Pharmaceuticals Inc
NASDAQ:IMPL
Debt Financing / Related
Impel Neuropharma Announces $100 Mln Royalty And Debt Financing Agreement With Oaktree
Published: 03/17/2022 13:37 GMT
Impel Pharmaceuticals Inc (IMPL) - Impel Neuropharma Announces $100 Million Royalty and Debt Financing Agreement With Oaktree.
Impel Neuropharma Inc - Transaction Provides Immediate, Non-dilutive Capital to Further Support Commercialization of Trudhesa.
Impel Neuropharma Inc - $100 Million in Gross Proceeds to Be Funded at Close, Extending Estimated Corporate Cash Runway Into 2024.
Impel Neuropharma Inc - Transaction Provides Immediate, Non-dilutive Capital to Further Support Commercialization of Trudhesa.
Impel Neuropharma Inc - $100 Million in Gross Proceeds to Be Funded at Close, Extending Estimated Corporate Cash Runway Into 2024.